Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors

Part of paid clinical trials in Greenville, South Carolina.

Sponsor
Prisma Health-Upstate
Study ID
NCT02938793
Phase
PHASE2
Status
Terminated

Conditions

  • Cancer
  • Rare Disease

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This is an investigator initiated single institution, open-label study to evaluate the antitumor activity, safety, and tolerability of durvalumab in combination with tremelimumab in subjects with select advanced rare solid tumors.

Key Dates

Start date
Dec 1, 2016
Status verified
Apr 2025
Primary completion
Sep 17, 2025
Completion
Sep 17, 2025

Study Design

Enrollment
92 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Single Arm
    Durvalumab, 1500 mg Q4W (equivalent to 20 mg/kg Q4W) intravenously for 13 doses and Tremelimumab 300mg intravenously as a single dose on cycle 1 day 1 only.

Primary Outcome Measure

Antitumor Activity [ Time Frame: 24 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Greenville Health System Cancer InstituteGreenvilleSouth Carolina29605-

Find similar trials in Greenville, SC

By research site
Greenville Health System Cancer Institute· Greenville, SC

Related Studies